Prague

Milan Kundera's 'remarkable' work explored oppression, inhumanity – and the absurdity of being human

Retrieved on: 
Thursday, July 13, 2023

It feels too soon, perhaps because in everything he wrote, he opened up new ways of thinking, writing and reading.

Key Points: 
  • It feels too soon, perhaps because in everything he wrote, he opened up new ways of thinking, writing and reading.
  • From the start, he was exposed to, and immersed in, the absurdity of human culture.
  • He grew up in Nazi-occupied Czechoslovakia, then lived under Stalinist rule, where he was an active member of the Communist Party.
  • I have been reading him, quoting him and teaching from his writings for decades, after bumping into his work in 1988.

Interrogating totalitarianism, with humour

    • But in each novel, Kundera offers some humour – often bitter, but capable of leavening the otherwise bleak, and densely reported, content.
    • But he also develops an erotic narrative that seems to suggest lighthearted sex can allow us to live fully in the moment.
    • Weight and lightness, laughter and forgetting, repetition and change, politics and sex: his first four novels incorporate such dualities.

Author in exile

    • In 1975, he fled his home for exile in France, and continued writing works of fiction that mostly followed the signature structure he first developed in The Joke: multi-part, multi-voiced novels, where the narrator interpolates critique, commentary and philosophical statements in the text.
    • This makes for a restless story, one that shifts to and fro across locations, times and contexts.
    • The focus of Kundera’s novels is their wrestle with questions of knowledge, the complexity of being and a constant uncertainty.

‘Things are not as simple as you think’

    • In The Art of the Novel (1986), he outlines a history of how novelists unpacked various dimensions of existence.
    • Homer never wondered whether, after all their many hand-to-hand battles, Achilles or Ajax still had all their teeth.
    • But for Don Quixote and Sancho teeth are a perpetual concern – hurting teeth, missing teeth.
    • Homer never wondered whether, after all their many hand-to-hand battles, Achilles or Ajax still had all their teeth.

Teller of inconvenient truths

    • He won other prizes, after all, among them the Jerusalem Prize in 1985 and the Herder Prize in 2000.
    • Perhaps it was his writing style that meant the Nobel committee saw him nominated on a number of occasions, but never awarded him the prize.
    • Robin Ashenden suggests he “had become a teller of truths inconvenient to the modern age”, and maybe there is something in that.

MiTAC Showcases New OCP Solutions at 2023 OCP Regional Summit

Retrieved on: 
Wednesday, April 19, 2023

PRAGUE, Czech Republic, April 19, 2023 /PRNewswire/ -- MiTAC Computing Technology, an industry-leading server and storage solution provider for enterprise, cloud and 5G edge computing, is proud to unveil its latest edge servers as part of its OCP solutions at the 2023 OCP Regional Summit, taking place at the Prague Congress Centre, booth #A13, from April 19-20.

Key Points: 
  • PRAGUE, Czech Republic, April 19, 2023 /PRNewswire/ -- MiTAC Computing Technology, an industry-leading server and storage solution provider for enterprise, cloud and 5G edge computing, is proud to unveil its latest edge servers as part of its OCP solutions at the 2023 OCP Regional Summit, taking place at the Prague Congress Centre, booth #A13, from April 19-20.
  • "These innovative solutions demonstrate our commitment to delivering cutting-edge server solutions for the ever-evolving needs of the cloud and 5G markets."
  • Building upon the improvements of ORv2, the Open Rack V3 benefits from a new bus bar design that aligns easily with OCP servers and power shelves.
  • MiTAC launches the 2OU OCP server sled Capri 2 , a single socket server that supports AMD EPYC™ 9004 processors.

Joint readout: Minister Champagne meets with U.S. Commerce Secretary Raimondo

Retrieved on: 
Friday, October 21, 2022

Minister Champagne and Secretary Raimondo discussed the passage of the U.S. CHIPS and Science Act of 2022 (CHIPS Act) and its implications for the North American semiconductor industry.

Key Points: 
  • Minister Champagne and Secretary Raimondo discussed the passage of the U.S. CHIPS and Science Act of 2022 (CHIPS Act) and its implications for the North American semiconductor industry.
  • The Secretary underscored the U.S.'s commitment to Canada-U.S.supply chain security in the semiconductor industry and highlighted this as a key areafor collaboration between the two nations.
  • SCC and NIST are working together to coordinate and collaborate on the development and alignment of artificial intelligence standards.
  • The Minister and the Secretaryemphasized the importance of standing together with allies and partners around the world in solidarity with a free and democratic Ukraine.

Taiwan, U.S. Collaborate to Strengthen 5G Supply Chain Resilience

Retrieved on: 
Friday, October 14, 2022

WASHINGTON, Oct. 14, 2022 /PRNewswire/ -- The Taiwan Industrial Development Bureau (IDB) under Taiwan Ministry of Economic Affairs coordinated an exhibit of Taiwanese 5G companies including HTC, QCT, Ufi Space, Lions, Askey, MTI, Lite-On, Compal, Edgecore and TMYTEK at the "5G Open RAN and AIoT Showcase" in the "5G & Smart City Pavilion" at Taiwan Expo USA 2022, held from October 12-14, 2022 in Washington, D.C. This showcase demonstrates how Taiwan offers great business potential for U.S. companies catering to the needs of both public and private networks in the global marketplace.

Key Points: 
  • Taiwan and U.S. companies collaborate to strengthen 5G supply chain resilience.
  • Recent trade relations between the U.S. and China have caused disruptions to the global supply chain.
  • Through the initial focus areas, including 5G, semiconductors and electric vehicles, U.S. and Taiwanese companies are developing closer partnerships to achieve supplier and supply chain diversity.
  • In recent years, IDB is responsible for industry promotion efforts to strengthen development of 5G and Open RAN within our industry.

Invibes Advertising NV: H1 2022 results: continued investments in a context of robust organic growth

Retrieved on: 
Wednesday, September 7, 2022

In the first half of 2022, Invibes Advertising maintained a strong growth pace, with a consolidated turnover up 52% at 13.3 million.

Key Points: 
  • In the first half of 2022, Invibes Advertising maintained a strong growth pace, with a consolidated turnover up 52% at 13.3 million.
  • This compares to an average annual growth rate (CAGR) of 54% for the 2016 to 2021 period.
  • This growth performance, including in the countries where the Company has been established the longest, shows the favourable positioning of Invibes Advertising, whose integrated technology platform offers its clients innovative digital advertising solutions for measurably more effective campaigns.
  • In line with its 2024 development roadmap, Invibes Advertising continued making the investments necessary to support its medium-term growth objectives, notably through a very strong commercial push.

SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Wednesday, November 3, 2021

Details on the upcoming presentations are below:

Key Points: 
  • Details on the upcoming presentations are below:
    Title: SO-C101, a high-affinity IL-15R agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations.
  • Selected presentation materials will be made available on the SOTIO Biotech website once the presentations conclude.
  • SOT101 (formerly SO-C101 or RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor chain.
  • SOT101 has been shown in pre-clinical models to synergize with checkpoint inhibitors and antibody therapies exerting ADCC.

ThreatMark Attracts Additional Funding; Appoints Daniel Rawlings as New CEO & President to Lead the Next Phase of Expansion & Growth

Retrieved on: 
Thursday, October 21, 2021

This technology leverages innovative fraud prevention & threat detection, combining advanced behavioral biometrics, real-time transaction risk monitoring & analysis, and comprehensive cybersecurity expertise.

Key Points: 
  • This technology leverages innovative fraud prevention & threat detection, combining advanced behavioral biometrics, real-time transaction risk monitoring & analysis, and comprehensive cybersecurity expertise.
  • ThreatMark's new CEO & President Daniel Rawlings commented on the news: "The increasingly sophisticated nature of modern threats and fraud require innovative solutions like ThreatMark.
  • The experience, industry expertise and relationship network that Dan brings to ThreatMark is a big step forward for us.
  • We are pleased to welcome Dan to the ThreatMark team and stand firmly behind them to help enable their planned expansion and growth."

SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021

PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.

Key Points: 
  • PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
  • DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.
  • The data demonstrate signs of efficacy and safety of DCVAC/OvCa combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma and provide strong rationale for potential study in larger clinical trials.
  • Our data indicate a potentially strong effect of DCVAC/OvCa in patients with ovarian cancer, predominantly in patients with immunologically cold tumors, which showed to be refractory in clinical trials with immunotherapy so far.

SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 11, 2021

b'SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.

Key Points: 
  • b'SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.
  • The presentation focuses on potentially predictive biomarker data from a phase 2 study of SOTIO\xe2\x80\x99s dendritic cell vaccine (DCVAC/OvCa) combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma after primary debulking surgery.\nSOTIO\xe2\x80\x99s DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique.
  • SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs.\nTitle: Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial\nPresenting Author: Lukas Rob, MD, PhD, University Hospital Kralovske Vinohrady (Prague, Czech Republic)\nA copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes, and a recorded oral presentation focused on the data will be hosted on the online ASCO Media Library.\nSOV01 is a randomized, open-label, three-arm multicenter Phase II clinical trial evaluating DCVAC/OvCa in combination with first-line standard chemotherapy in women with newly diagnosed epithelial ovarian cancer following radical debulking surgery.\n'

Uneven progress towards green recovery as EU members submit spending plans to access EUR 672 billion fund

Retrieved on: 
Thursday, April 29, 2021

As of February most plans were kept secret, and consultations with the public were rare [2].

Key Points: 
  • As of February most plans were kept secret, and consultations with the public were rare [2].
  • In Estonia, the government plans measures that disregard conservation and a decreasing carbon sink, in spite of recommendations from the Commission and environmental groups.
  • We also need grants to support household energy efficiency renovations and a clearer financial set-up to help local, renewable energy communities access funding.
  • We provided recommendations on the over-400-page draft plan, and improvements are possible if these are considered.\xe2\x80\x9d\n'